Literature DB >> 17437616

The societal costs of intracerebral hemorrhage in Spain.

P Navarrete-Navarro1, W M Hart, J Lopez-Bastida, M C Christensen.   

Abstract

This study estimates the lifetime societal costs associated with incident intracerebral hemorrhage (ICH) in Spain. An epidemiological model of ICH incidence, survival and morbidity was developed using retrospective data from 28 hospitals in Andalusia and published data identified in a systematic literature review. Data on resource utilization and costs were obtained from five hospitals in the Canary Islands, whereas cost of outpatient care, informal care and lost productivity were obtained from standardized questionnaires completed by survivors of ICH. The lifetime societal costs of incident ICH in Spain is estimated at 46,193 euros per patient. Direct medical costs accounted for 32.7% of lifetime costs, whilst 67.3% were related to indirect costs. One-third of direct medical costs over the first year were attributable to follow-up care, including rehabilitation. Indirect costs were dominated by costs of informal care (71.2%). The aggregated lifetime societal costs for the estimated 12,534 Spanish patients with a first-ever ICH in 2004 was 579 million euros. ICH implies substantial costs to society primarily due to formal and informal follow-up care and support needed after hospital discharge. Interventions that offer survival benefits without improving patients' functional status are likely to further increase the societal costs of ICH.

Entities:  

Mesh:

Year:  2007        PMID: 17437616     DOI: 10.1111/j.1468-1331.2007.01756.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  A literature review of indirect costs associated with stroke.

Authors:  Heesoo Joo; Mary G George; Jing Fang; Guijing Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-06-21       Impact factor: 2.136

2.  Economic impact of patients admitted to stroke units in Spain.

Authors:  Jose Alvarez-Sabín; Manuel Quintana; Jaime Masjuan; Juan Oliva-Moreno; Javier Mar; Nuria Gonzalez-Rojas; Virginia Becerra; Covadonga Torres; María Yebenes
Journal:  Eur J Health Econ       Date:  2016-04-15

3.  Identifying the Conditions for Cost-Effective Minimally Invasive Neurosurgery in Spontaneous Supratentorial Intracerebral Hemorrhage.

Authors:  Floris H B M Schreuder; Mirre Scholte; Marike J Ulehake; Lotte Sondag; Maroeska M Rovers; Ruben Dammers; Catharina J M Klijn; Janneke P C Grutters
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

4.  Association between disability measures and short-term health care costs following intracerebral hemorrhage.

Authors:  Michael C Christensen; Stephen Morris
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.210

5.  Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain.

Authors:  Julio Lopez-Bastida; Juan Oliva Moreno; Melany Worbes Cerezo; Lilisbeth Perestelo Perez; Pedro Serrano-Aguilar; Fernando Montón-Álvarez
Journal:  BMC Health Serv Res       Date:  2012-09-12       Impact factor: 2.655

Review 6.  Cost of disorders of the brain in Spain.

Authors:  Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

7.  Economic valuation of informal care in cerebrovascular accident survivors in Spain.

Authors:  Juan Oliva-Moreno; Isaac Aranda-Reneo; Cristina Vilaplana-Prieto; Almudena González-Domínguez; Alvaro Hidalgo-Vega
Journal:  BMC Health Serv Res       Date:  2013-12-05       Impact factor: 2.655

8.  [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].

Authors:  Ginés Escolar-Albaladejo; Gonzalo Barón-Esquivias; José Luis Zamorano; Lourdes Betegón-Nicolás; Cristina Canal-Fontcuberta; Marina de Salas-Cansado; Darío Rubio-Rodríguez; Carlos Rubio-Terrés
Journal:  Aten Primaria       Date:  2016-01-30       Impact factor: 1.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.